In a new development, Premera, an affiliate of Blue Cross, has filed a modified version of its previously rejected class action against Takeda Pharmaceuticals. The lawsuit alleges that Takeda conspired to prevent generic versions of the irritable bowel syndrome (IBS) drug, Amitiza, from entering the market. A Massachusetts federal judge dismissed the original suit filed by Premera. However, undeterred, the health insurance organization promptly revised and filed a fresh suit.
Information regarding this lawsuit comes from a recent report by Law360. The updated suit comes a few weeks after the initial attempt was dismissed by the judge. The unfolded scenario showcases Premera’s commitment to challenging Takeda Pharmaceuticals over what they perceive to be stifling competition in the market for Amitiza.
The persistent legal confrontation underscores an increasingly volatile pharmaceutical market. It also reflects the hurdles that companies face when trying to establish the availability of generic alternatives. As the situation continues to evolve, legal professionals and key players in the pharmaceutical industry round the globe will undoubtedly watch for further developments.